1. Taiwan Stocks

  2. •

    Finance

  3. •

    Investment managers
Diamond BioFund Inc.

Diamond BioFund Inc.

TTWSE:6901
16.75
TWD
-0.55
(-3.18%)
3.42EPS
5.47P/E
16.04BMarket Cap
Nov 16Next Earn
Diamond BioFund Inc.
TWSE:6901
(Taiwan Stock Exchange)

Recent

price

16.75

P/E

ratio

5.47

div

yld

- -

ROIC.AI

2019
2020
2021
2022
2023
2024
2025
TTM
TWD
- -
- -
- -
- -
- -
- -
- -
- -
Revenue per Share
-0.55
6.19
3.01
1.06
-3.32
-2.96
-1.38
3.44
Basic EPS, GAAP
-0.06
-0.07
-0.32
0.63
-3.32
1.32
-0.31
-0.34
Free Cash Flow per Basic Share
- -
- -
- -
0.2
0.16
- -
- -
- -
Dividend per Share
4.02
12.14
13.87
14.75
15.13
12.18
10.81
14.43
Book Value per Share
4.02
12.14
13.87
14.75
15.13
12.18
10.81
14.43
Tangible Book Value per Share
674
983
949
749
779
850
852
851
Basic Weighted Avg Shares
- -
- -
- -
- -
- -
- -
- -
- -
Sales/Revenue/Turnover
- -
- -
- -
- -
- -
- -
- -
- -
Operating Margin (%)
11
12
12
11
10
29
28
27
Depreciation Expense
-371
6,090
2,852
798
-2,583
-2,518
-1,175
2,924
Net Income, GAAP
- -
0.41
3.68
9.46
- -
- -
- -
- -
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
1,255
8,018
9,892
10,597
9,590
4,932
3,838
7,172
Working Capital
52
43
33
- -
114
94
69
57
LT Debt
3,011
9,100
10,392
11,050
12,862
10,373
9,221
12,310
Total Equity
- -
99.15
-1
-1.15
- -
- -
- -
-1.43
Return on Invested Capital (%)
- -
99.65
29.13
7.43
- -
- -
- -
26.77
Return on Capital (%)
- -
100.56
29.26
7.44
-21.61
-21.67
-11.99
26.97
Return on Common Equity (%)

Capital Structure

TWD

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
25
25
25
LT Borrowings
- -
- -
- -
LT Finance Leases
69
63
57
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
853
853
853
Market Capitalization
14,070
11,855
16,043

Working Capital

TWD

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
3,906
3,753
7,242
Cash, Cash Equivalents & STI
3,891
3,737
7,224
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
69
62
69
Payables & Accruals
- -
- -
- -
ST Debt
25
25
25
Deferred Revenue
- -
- -
- -

Growth Rates

TWD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
1.29%
-11.11%
Free Cash Flow
- -
-172.28%
-123.55%
Net Income, GAAP
- -
-120.98%
-53.35%
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

TWD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

TWD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-0.95
-0.16
-0.95
-0.9
-2.96
2025
-0.67
-0.52
-0.17
-0.02
-1.38
2026
-0.42
4.04
- -
- -
- -

Quarterly Dividends Per Share

TWD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Similar Companies
Morgan Stanley (NYSE:MS)
BlackRock, Inc. (NYSE:BLK)
Motilal Oswal Financial Services Limited (NSE:MOTILALOFS)
HDFC Asset Management Co. Ltd. (NSE:HDFCAMC)
Blackstone Inc. (NYSE:BX)
360 One Wam Limited (NSE:360ONE)
Business
Diamond Biofund Inc. (6901.TWO) is a Taiwan-based venture capital firm specializing in evergreen funds focused on biotechnology and medical investments. The company provides venture capital financing to startups and early-stage ventures in new drug research and development; high-end medical equipment; innovative medical services, technologies, and channels; medical access; and agricultural biotechnology, with primary operations in Taiwan and Greater China markets. Founded in 2013 and headquartered at 10F, No. 236, Section 4, Xinyi Road, Xinyi District, Taipei, Taiwan, Diamond Biofund manages investments through equity stakes in portfolio companies including StemCyte, CHO Pharma, Sinew Pharma, Rejuvenate Bio, ImmunAdd, Syncell, EyeYon, Theia Medical, Tetanti AgriBiotech, and others across cell/gene therapy, glycoscience, liver disease treatments, gene therapy, vaccine adjuvants, proteomics platforms, synthetic corneal implants, artificial retinal implants, and organic waste processing technologies. Recent developments include StemCyte's listing on Taiwan's Emerging Stock Board in December 2024 following U.S. FDA BLA approval for its RegeneCyte umbilical cord blood product and successful Phase IIa trial results for post-COVID syndrome treatment; Syncell's completion of a $15 million Series A funding round in December 2024 and recognition as one of The Scientist's Top 10 Innovations of 2024; Rejuvenate Bio's licensing agreements for mitral valve disease treatments with an international animal pharmaceutical company and a Taiwanese pet healthcare firm; ImmunAdd's completion of GMP manufacturing and DMF submission for its IA-05 synthetic saponin vaccine adjuvant, with ongoing negotiations for global collaborations; EyeYon's receipt of U.S. IDE approval, EU MDR certification, and progress in China's pivotal trial for its EndoArt synthetic corneal implant; Theia's first-in-human artificial retinal implant surgery in February 2025; and Tetanti AgriBiotech's agreement with a listed green energy company for a large-scale organic waste treatment plant.